WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19 th Annual Global Healthcare Conference on Friday, September 10, 2021 at 4:15 p.m. ET.
A live webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com . An archived replay of the webcast will be available on the Company’s website following the event.
About TScan Therapeutics, Inc.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Contacts
Media Contact:
David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com
Investor Contact:
Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com